As­traZeneca ax­es li­cense agree­ment with Aridis, plac­ing Eu­rope-fund­ed PhI­II on hold

As­traZeneca is scrap­ping its li­cense agree­ment with Aridis Phar­ma­ceu­ti­cals on March 30, the British Big Phar­ma told the biotech last week, send­ing a Eu­ro­pean-fund­ed Phase III in­to stor­age.

With the li­cense ter­mi­nat­ed for AR-320, al­so known as su­vra­tox­um­ab, Aridis can no longer con­tin­ue a late-stage clin­i­cal tri­al test­ing the mon­o­clon­al an­ti­body as a pre­emp­tive treat­ment for me­chan­i­cal­ly ven­ti­lat­ed pa­tients in in­ten­sive care who are col­o­nized with S. au­reus. The SAATEL­LITE-2 tri­al kicked off in Sep­tem­ber and was ex­pect­ed to en­roll 564 pa­tients who don’t have ven­ti­la­tor-as­so­ci­at­ed pneu­mo­nia, or VAP.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN